Squarepoint
AVTX icon

Squarepoint’s Avalo Therapeutics AVTX Stock Holding History

Squarepoint’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
81,285
+40,431
+99% +$632K ﹤0.01% 2610
2025
Q4 		$742K Buy
+40,854
New +$690K ﹤0.01% 2867
2021
Q4 		– Sell
-6
Closed -$41K – 3151
2021
Q3 		$41K Buy
+6
New +$48.6K ﹤0.01% 2789
2021
Q2 		– Sell
-9
Closed – – 3215
2021
Q1 		$0 Hold
9
– – ﹤0.01% 3099
2020
Q4 		$0 Hold
9
– – ﹤0.01% 2910
2020
Q3 		$58K Sell
9
-3
-25% -$22.5K ﹤0.01% 2353
2020
Q2 		$92K Sell
12
-5
-29% -$36.3K ﹤0.01% 2031
2020
Q1 		$119K Buy
+17
New +$180K ﹤0.01% 1605

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Squarepoint's AVTX Position: Q1 2026 in Review

Squarepoint increased its Avalo Therapeutics (AVTX) stake by 99% in Q1 2026, buying an estimated $632K and bringing the position to 81,285 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2610.

Squarepoint first reported a position in AVTX in Q1 2020 and has held it in 8 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Squarepoint held 81,285 shares of Avalo Therapeutics worth $1.21M as of Q1 2026.
  • Squarepoint bought 40,431 Avalo Therapeutics shares in Q1 2026, an estimated $632K.
  • Avalo Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2610 holding.
  • Squarepoint first reported a position in Avalo Therapeutics in Q1 2020 and has held it in 8 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.